Name | Title | Contact Details |
---|
Omasky Group is a Hinesburg, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St. Ann`s Community is Rochester`s leading senior housing and health services provider, with a tradition of quality care for older adults dating back to 1873. St. Ann`s offers a continuum of care that includes independent retirement living, assisted living, skilled nursing, memory care, short-term transitional care, palliative care, and adult day programs. One of the area`s largest employers, St. Ann`s has more than 1,200 employees who are "Caring for the Most Important People on Earth."
Curaleaf (CSE: CURA) is a leading vertically integrated cannabis operator in the United States. Headquartered in Wakefield, Massachusetts, Curaleaf is located in 10 states and owns and operates 26 dispensaries, 10 cultivation sites and 9 processing sites with a focus on highly populated, limited license states, including Florida, Massachusetts, New Jersey and New York. Here at Curaleaf, we leverage our extensive research and development capabilities to distribute cannabis products in multiple formats with the highest standard for safety, effectiveness, consistent quality and customer care. We are committed to being the industry`s leading resource in education and advancement through research and advocacy, and our Florida operations were the first in the cannabis industry to receive the Safe Quality Food certification under the Global Food Safety Initiative, setting a new standard of excellence. Our Curaleaf network of operating companies collectively employs a national workforce of over 500 people. Plans for additional growth are actively in place.
Coordinated Health Center is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.